EWTX - Edgewise Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.09
DETAILS
HIGH:
$66.00
LOW:
$25.00
MEDIAN:
$52.00
CONSENSUS:
$49.09
UPSIDE:
28.07%
About Edgewise Therapeutics, Inc. (https://www.edgewisetx.com)
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Kevin Koch | President, Chief Executive Officer & Director | 1960 | $1,146,300 USD |
| Behrad Derakhshan | Chief Operating Officer | 1980 | $803,100 USD |
| Joanne Donovan | Chief Medical Officer | 1957 | $788,323 USD |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director | 1970 | $737,866 USD |
| Michael Nofi | Chief Financial Officer | 1971 | $97,700 USD |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman | 1960 | $80,000 USD |
| Badreddin Edris | Co-Founder & Independent Director | 1987 | $55,000 USD |
| Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs | – | – |
| John R. Moore | General Counsel | 1964 | – |